Every Form 4 that Eastman Chemical Company (EMN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow EMN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EMN filings page.
EASTMAN CHEMICAL CO (EMN) director James J. O'Brien reported several gift transfers of common stock on September 2, 2026. He made bona fide gifts of 5,378 shares held directly and 2,482 shares held indirectly through a revocable trust, and an associated family trust is reported as receiving 7,860 shares. After these transactions, he holds 1,628 shares directly and 7,860 shares indirectly through the O'Brien Family Dynasty Trust. No transactions are reported under a Rule 10b5-1 trading plan.
Eastman Chemical Company senior vice president and chief human resources officer Adrian James Holt reported selling 3,283 shares of common stock on August 4, 2026 at $71.31 per share in a sale described as an open market or private transaction, leaving 0 directly held common shares reported after the sale.
Eastman Chemical Company senior vice president and chief human resources officer Adrian James Holt reported routine equity compensation activity involving restricted stock units. On June 1, 2026, 4,341 restricted stock units granted on June 1, 2023 vested and were settled into an equal number of common shares. To cover tax obligations on this vesting, 1,058 common shares were withheld rather than sold in the open market. After these transactions, Holt directly holds 3,283 shares of Eastman Chemical common stock, and the vested restricted stock unit award has been fully converted into shares.
Alfonso Humberto P reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical director Humberto P. Alfonso received a grant of 1,628 Phantom Stock Units on May 7, 2026. These units are part of the Directors' Deferred Compensation Plan and each unit’s value equals one share of Eastman common stock.
The award represents the deferral, at the director’s election, of the value of his annual non-employee director restricted stock award that would otherwise have been paid in common stock. The Phantom Stock Units vest on May 7, 2027 and are payable only in cash. Following this grant, the director holds 57,588 Phantom Stock Units in total.
BEGEMANN BRETT D reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical director Brett D. Begemann reported a routine compensation transaction involving phantom stock units tied to Eastman Chemical common stock. He received an award of 1,628 Phantom Stock Units, each valued at $73.69, credited under the company’s Directors' Deferred Compensation Plan.
These units are unvested, will vest on May 7, 2027, and are payable only in cash, meaning they do not represent actual shares or voting rights. Following this award, Begemann now holds 60,034 Phantom Stock Units in total, reflecting deferred, cash-settled director compensation rather than an open-market stock purchase.
Mink Kim Ann reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical director Kim Ann Mink reported receiving a grant of 1,628 Phantom Stock Units tied to the company’s common stock value at $73.69 per unit. This compensation-related award increases her Phantom Stock Unit balance to 17,280 units. The units are unvested, will vest on May 7, 2026, and are payable only in cash under the Directors' Deferred Compensation Plan. The grant reflects her election to defer the value of an annual non-employee director restricted stock award that otherwise would have been paid in common stock.
SLAGER DONALD W reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical Company director Donald W. Slager received an equity grant of 1,628 shares of common stock. This was a grant or award, not an open-market purchase or sale, and carried a price of $0.00 per share as compensation rather than a cash transaction.
The shares are restricted, with restrictions scheduled to lapse on May 7, 2027, subject to conditions tied to his continued service as a director. Following this grant, Slager directly holds a total of 3,303 shares of Eastman Chemical common stock.
Holder Julie Fasone reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical director Julie Fasone Holder received a grant of 1,628 shares of common stock as a restricted stock award. The shares were granted at no cash cost and will remain restricted until May 7, 2027, contingent on her continued service as a director. Following this award, she directly holds 19,174 shares of Eastman Chemical common stock.
Eastman Chemical Company director Renee J. Hornbaker received a grant of 1,628 shares of common stock as a restricted stock award. The restrictions are scheduled to lapse on May 7, 2027, subject to her continued service as a director. Following this award, she directly holds 25,565 shares, which include 154 shares acquired through automatic dividend reinvestment since May 1, 2025.
OBRIEN JAMES J /KY reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical director James J. O'Brien received a grant of 1,628 shares of common stock as a restricted stock award. The award was granted at no cash cost and represents his annual Restricted Stock Award. After this grant, he holds 8,456 shares directly.
The restricted shares are scheduled to lapse on May 7, 2027, subject to conditions tied to his continued service as a director. In addition to his direct holdings, he also indirectly owns 1,022 shares through a revocable trust.
BUTLER ERIC L reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical director Eric L. Butler received a grant of 1,628 shares of common stock as a restricted stock award. The shares were awarded at no cash cost per share and represent his annual Restricted Stock Award as a director. Following this grant, Butler directly holds 10,958 shares of Eastman Chemical common stock. The restrictions on these shares will lapse on May 7, 2027, subject to conditions tied to his continued service as a director.
Eastman Chemical Company director Linnie M. Haynesworth received an annual equity grant in the form of restricted common shares. On May 7, 2026, she acquired 1,628 shares at no cash price as a grant or award, increasing her direct holdings to 3,135 shares. These are restricted shares, with restrictions scheduled to lapse on May 7, 2027, subject to conditions related to her continued service as a director. The share amount represents her annual Restricted Stock Award, reflecting routine director compensation rather than an open-market purchase or sale.
Audia Damon J reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical director Damon J. Audia reported a compensation-related grant of 1,628 Phantom Stock Units on May 7, 2026. These units, each valued at $73.69, are credited under the Directors' Deferred Compensation Plan and bring his total phantom units to 4,274.
The units will vest on May 7, 2027 and are payable only in cash, not stock. According to the footnotes, this represents a deferral of the value of his annual non-employee director restricted stock award that otherwise would have been paid in common shares, making this a routine, non-market transaction.
Eastman Chemical Company senior vice president Adrian James Holt reported selling common stock and settling deferred compensation units. On May 5, 2026, he executed an open-market sale of 1,709 shares of common stock at $77.05 per share, leaving no directly held shares from this position in the filing. The same day, he disposed of 2,271 Phantom Stock Units to the issuer under an Executive Deferred Compensation Plan, each unit valued based on the closing price of Eastman Chemical common stock on the disposition date, also leaving no remaining units from this grant.
Eastman Chemical director Damon J. Audia reported routine compensation-related transactions involving cash-settled Phantom Stock Units tied to Eastman Chemical common stock. On April 8, 2026, he acquired 852 units at a reference value of $74.72 per unit and another 408 units. These units reflect voluntary and automatic deferrals of director retainer fees and reinvested dividend equivalents under the company’s Directors' Deferred Compensation Plan, and are payable only in cash after his board service ends. Following these awards, his balance increased to 2,646 Phantom Stock Units, with no open‑market share purchases or sales disclosed.
BUTLER ERIC L reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical director Eric L. Butler received a grant of 408 Phantom Stock Units as compensation. These units were credited under the Directors' Deferred Compensation Plan as an automatic deferral of a portion of his annual cash retainer fees.
Each Phantom Stock Unit tracks the market value of one share of Eastman Chemical common stock but is payable only in cash after he terminates service as a director. Following this grant and dividend equivalents reinvested in additional units, Butler now holds a total of 3,228 Phantom Stock Units under the plan.
BEGEMANN BRETT D reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical director Brett D. Begemann increased his deferred compensation balance through phantom stock units rather than cash fees. On April 8, 2026, he was credited with 1,159 Phantom Stock Units valued at $74.27 each and an additional 408 units at $0 under the company’s Directors' Deferred Compensation Plan. These units track the value of one share of Eastman common stock but are payable only in cash after his board service ends. Following these awards and fee deferrals, Begemann holds 58,408 phantom stock units directly, including amounts from voluntary and automatic fee deferrals and reinvested dividend equivalents.
Haynesworth Linnie M reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical director Linnie M. Haynesworth received 408 Phantom Stock Units on April 8, 2026, as a grant under the company’s Directors’ Deferred Compensation Plan. These units track the value of one share of Eastman common stock but are payable only in cash after board service ends.
The award increased Haynesworth’s Phantom Stock Unit balance to 5,640 units. The grant reflects an automatic deferral of a portion of the director’s annual retainer fees, with dividend equivalents reinvested into additional units, and does not represent an open-market stock purchase or sale.
OBRIEN JAMES J /KY reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical director James J. O'Brien received 408 Phantom Stock Units credited under the company’s Directors' Deferred Compensation Plan. These units mirror the market value of one share of common stock each but are payable only in cash after he ceases serving as a director.
The award represents an automatic deferral of a portion of his annual retainer fees that would otherwise have been paid in cash. Following this grant, O'Brien holds a total of 18,137 Phantom Stock Units, which also include dividend equivalents that have been reinvested into additional units.
Alfonso Humberto P reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical director Humberto P. Alfonso reported two compensation-related grants of Phantom Stock Units tied to company common stock. On April 8, 2026, he was credited with 988 Phantom Stock Units at a reference value of $74.27 per unit and 408 additional units at $0.00 per unit.
After these transactions, his reported Phantom Stock Unit balance increased to 55,961 units. The footnotes explain these units are credited under the Directors' Deferred Compensation Plan, have a value equal to one share of Eastman Chemical common stock, and are payable only in cash after his service as a director ends.
The filing notes these units arise from a mix of voluntary deferral of retainer fees, automatic deferral of annual retainer fees into a director stock account, and dividend equivalents reinvested into additional Phantom Stock Units. These are administrative, non-market transactions rather than open-market share purchases or sales.
Holder Julie Fasone reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical director Julie Fasone Holder received 408 Phantom Stock Units as a compensation award. These units are credited under the Directors' Deferred Compensation Plan, with each unit valued like one share of Eastman common stock but payable only in cash after she leaves the board.
This grant arose from the automatic deferral of a portion of her annual director retainer that would otherwise have been paid in cash, and it also reflects dividend equivalents that are reinvested into additional Phantom Stock Units. Following this award, she now holds a total of 15,051 Phantom Stock Units.
SLAGER DONALD W reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical Company director Donald W. Slager received a compensation grant of 408 Phantom Stock Units. These units were credited under the Directors' Deferred Compensation Plan at no purchase price and each unit tracks the value of one share of common stock.
The award represents an automatic deferral of a portion of the director’s annual cash retainer, with amounts payable only in cash after his service as a director ends. Following this grant, Slager holds a total of 1,699 Phantom Stock Units, including units from prior awards and dividend equivalents reinvested in additional units.
HORNBAKER RENEE J reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical Company director Renee J. Hornbaker received an award of 408 Phantom Stock Units tied to the value of the company’s common stock. These units were credited under the Directors' Deferred Compensation Plan as an automatic deferral of a portion of her annual retainer fees.
Each Phantom Stock Unit is payable only in cash after she terminates service as a director and includes dividend equivalents reinvested into additional units. After this grant, she holds a total of 51,107 Phantom Stock Units.
Mink Kim Ann reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical director Kim Ann Mink received a grant of 408 Phantom Stock Units on April 8, 2026. These units track the value of one share of common stock each but are payable only in cash after her service as a director ends. The grant represents an automatic deferral of a portion of her annual cash retainer fees and includes dividend equivalents reinvested in additional units. Following this award, she holds a total of 15,653 Phantom Stock Units credited under the Directors' Deferred Compensation Plan.
Holt Adrian James reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical senior vice president and chief human resources officer Adrian James Holt received new equity awards. On February 24, 2026, he was granted 32,116 employee stock options and 4,419 restricted stock units at a grant price of $0.00 per unit as compensation.
One-third of the options become exercisable on February 24, 2027, February 24, 2028, and February 24, 2029. Each restricted stock unit represents the right to receive one share of common stock and will vest and pay out in unrestricted shares on February 24, 2029, subject to continued employment.
Eastman Chemical’s Controller & CAO, Michelle Renee Stewart, reported equity awards consisting of stock options and restricted stock units. She was granted 11,075 employee stock options at an exercise price of $0.00 per option and 1,524 restricted stock units, all held as direct ownership.
According to the award terms, one-third of the options become exercisable on each of February 24, 2027, February 24, 2028, and February 24, 2029. Each restricted stock unit represents a contingent right to receive one share of Eastman Chemical common stock. The restricted stock units will vest and pay out in unrestricted shares on the third anniversary of the grant date, February 24, 2029, subject to continued employment.
McAlindon Julie A. reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical senior vice president Julie A. McAlindon received new equity awards on February 24, 2026. She was granted 24,364 employee stock options, which become exercisable in three equal parts on February 24, 2027, February 24, 2028, and February 24, 2029.
She was also awarded 3,352 restricted stock units, with each unit representing the right to receive one share of common stock. These units will vest and pay out in unrestricted shares on February 24, 2029, subject to her continued employment.
Eastman Chemical CEO Mark J. Costa reported equity awards, not open-market trades. He received an employee stock option grant covering 232,559 shares at an exercise price of $0.00 per option. One-third of these options becomes exercisable on February 24, 2027, 2028, and 2029, respectively.
Costa was also granted 31,993 restricted stock units, each representing a contingent right to one share of Eastman Chemical common stock. These restricted stock units are scheduled to vest and pay out in unrestricted shares on February 24, 2029, subject to continued employment.
Eastman Chemical Company executive Brian Travis Smith received new equity awards. On February 24, 2026, he was granted 53,157 employee stock options with an exercise price of $0.0000 per option. One-third of these options become exercisable on February 24, 2027, February 24, 2028, and February 24, 2029, respectively.
He was also granted 7,313 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Eastman Chemical common stock, and these units will vest and pay out in unrestricted shares on the third anniversary of the grant date, February 24, 2029, subject to continued employment.
Caveness Michelle H reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical Company senior vice president and Chief Manufacturing Officer Michelle H. Caveness reported equity awards granted on February 24, 2026. She received 33,223 employee stock options with one-third becoming exercisable on February 24 of 2027, 2028, and 2029.
She was also granted 4,571 restricted stock units, each representing the right to receive one share of common stock. These RSUs will vest and pay out in unrestricted shares on February 24, 2029, subject to continued employment.
Gbadegesin Bosede Ikeolu reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical Company senior vice president, chief legal officer and corporate secretary Bosede Ikeolu Gbadegesin received equity awards as part of compensation. She was granted employee stock options for 33,223 shares on February 24, 2026, with one‑third becoming exercisable on February 24 of 2027, 2028 and 2029.
She also received 4,571 restricted stock units on the same date. Each unit represents the right to receive one share of common stock, and these RSUs vest and pay out in unrestricted shares on February 24, 2029, subject to continued employment.
Eastman Chemical Company executive Brad A. Lich reported equity awards granted as part of his compensation. On February 24, 2026, he acquired employee stock options for 63,123 shares of common stock at a grant price of $0 per option.
One-third of these options become exercisable on February 24, 2027, February 24, 2028, and February 24, 2029. He also received 8,684 restricted stock units, each representing one share of common stock, which will vest and pay out in unrestricted shares on February 24, 2029, subject to continued employment.
McLain William Thomas Jr. reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical executive vice president and CFO William Thomas McLain Jr. reported equity awards consisting of 59,801 employee stock options and 8,227 restricted stock units, both granted at a price of $0 per unit.
One-third of the options become exercisable on February 24, 2027, February 24, 2028, and February 24, 2029. Each restricted stock unit represents the right to receive one share of common stock and will vest and pay out in unrestricted shares on February 24, 2029, subject to continued employment.
Eastman Chemical Company executive Brad A. Lich, EVP & CCO, reported a tax-related share disposition on common stock. On February 18, 2026, 5,569 shares were withheld at $80.26 per share to cover tax obligations tied to the payout of performance shares for the 2023–2025 performance period. After this transaction, he directly owned 96,779 common shares, with additional indirect holdings through an ESOP and a 401(k) plan.
Eastman Chemical Company senior vice president Adrian James Holt reported a routine tax-withholding share disposition. On this Form 4, 588 shares of common stock were withheld at a price of $80.26 per share to cover tax obligations from the payout of performance shares for the 2023-2025 performance period. After this non-market transaction, Holt directly holds 1,709 shares of Eastman Chemical common stock.
Eastman Chemical Company executive reports tax-related share withholding. EVP, AFP, Mfg., WWEC & HSE Brian Travis Smith had 3,086 shares of common stock withheld at $80.26 per share on a tax-withholding disposition related to performance shares for the 2023–2025 performance period, leaving him with 24,235 directly owned shares.
Eastman Chemical Company senior vice president Julie A. McAlindon reported a tax-related share disposition involving company common stock. On February 18, 2026, 1,812 shares of common stock were withheld at $80.26 per share to satisfy tax obligations tied to a performance share payout for the 2023-2025 performance period.
After this withholding, McAlindon directly owned 18,199 shares of Eastman Chemical common stock. She also indirectly held 887 shares through an ESOP arrangement, reflecting separate plan-related ownership.
Eastman Chemical Company senior vice president Michelle H. Caveness had 528 shares of common stock withheld on February 18, 2026 to cover tax obligations tied to a performance share payout for the 2023–2025 period.
After this tax-withholding disposition, she directly owned 7,655 shares of Eastman Chemical common stock.
Eastman Chemical Company Controller and Chief Accounting Officer Michelle Renee Stewart reported a tax-related share disposition. On the reported date, 1,063 shares of common stock were withheld at a price of $80.26 per share to cover tax obligations tied to the payout of performance shares for the 2023-2025 performance period. After this withholding, her directly owned common stock holdings were 7,209 shares.
Eastman Chemical executive vice president and CFO William Thomas McLain Jr. reported a tax-related share disposition involving company common stock. On the reported date, 4,471 shares were withheld at a price of $80.26 per share to cover tax obligations tied to the payout of performance shares for the 2023–2025 performance period. After this tax-withholding disposition, he directly held 65,313 shares of Eastman Chemical common stock.
Eastman Chemical CEO and board chair Mark J. Costa reported a tax-related share disposition. On the payout of performance shares for the 2023-2025 performance period, 25,260 shares of common stock were withheld to cover tax obligations at a price of $80.26 per share. After this withholding, Costa directly owns 497,929 shares of Eastman Chemical common stock, and indirectly holds 3,227 shares through an ESOP arrangement.
Eastman Chemical executive Stephen Glenn Crawford, EVP and Chief Technology and Sustainability Officer, had 4,720 shares of common stock withheld on February 18, 2026 at $80.26 per share to cover tax obligations from a 2023–2025 performance share payout. After this tax-withholding disposition, he holds 67,714 common shares directly, plus additional indirect holdings through 401(k) and ESOP accounts for himself and his spouse.
Eastman Chemical executive Brad A. Lich reported an equity award of company stock. On February 11, 2026, the EVP & CCO acquired 18,861 shares of Eastman Chemical common stock at $0 per share as a grant based on performance for the three-year 2023–2025 period.
After this award, Lich beneficially owned 102,348 common shares directly, plus 2,594 shares indirectly through a 401(k) plan and 1,251 shares indirectly through an ESOP, reflecting his combined direct and plan-based holdings in Eastman Chemical.
McLain William Thomas Jr. reported acquisition or exercise transactions in a Form 4 filing for EMN. The filing lists transactions totaling 15,883 shares. Following the reported transactions, holdings were 69,784 shares.
Eastman Chemical executive Stephen G. Crawford received an equity award of company stock. On February 11, 2026, he acquired 12,133 shares of Eastman Chemical common stock at a price of $0 per share, reported as a grant or award tied to performance.
This award, based on the determination of performance shares earned for the three-year 2023–2025 period, increased his direct holdings to 72,434 common shares. He also reports indirect ownership through benefit and retirement plans: 459 shares by a 401(k) plan, 296 shares by his spouse in an ESOP, 1,134 shares by an ESOP, and 64 shares by his spouse in a 401(k) plan.
Stewart Michelle Renee reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical Controller and Chief Accounting Officer Michelle Renee Stewart received an award of 3,309 shares of common stock on February 11, 2026 at a price of $0 per share. The award reflects the determination of performance shares earned for the three-year 2023–2025 performance period. Following this grant, she directly owns 8,272 Eastman Chemical common shares.
Costa Mark J reported acquisition or exercise transactions in a Form 4 filing for EMN. The filing lists transactions totaling 64,192 shares. Following the reported transactions, holdings were 523,189 shares.
Eastman Chemical executive Julie A. McAlindon reported an equity award of company stock. On February 11, 2026, she acquired 7,280 shares of Eastman Chemical common stock at a price of $0 per share, reported as a grant, award, or other acquisition.
The footnote explains this reflects the determination of performance shares earned for the three-year 2023–2025 performance period, meaning the award was tied to multi‑year performance goals. After this grant, McAlindon directly beneficially owned 20,011 common shares, and indirectly beneficially owned an additional 887 shares through an ESOP.
Caveness Michelle H reported acquisition or exercise transactions in a Form 4 filing for EMN. The filing lists transactions totaling 1,937 shares. Following the reported transactions, holdings were 8,183 shares.
Eastman Chemical executive Brian Travis Smith acquired 10,589 shares of common stock on February 11, 2026 through a performance award. The shares were granted at a price of $0 per share following the determination of performance shares earned for the 2023–2025 period.
After this award, Smith directly beneficially owns 27,321 shares of Eastman Chemical common stock.